HC Wainwright restated their buy rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $13.00 price objective on the biotechnology company’s stock.
Aurinia Pharmaceuticals Stock Up 5.1 %
NASDAQ:AUPH opened at $7.26 on Friday. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.24. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.04 billion, a P/E ratio of -16.88 and a beta of 1.44. The stock’s fifty day simple moving average is $5.94 and its 200-day simple moving average is $5.53.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.08) earnings per share. Equities research analysts expect that Aurinia Pharmaceuticals will post 0.13 earnings per share for the current year.
Insiders Place Their Bets
Institutional Trading of Aurinia Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of AUPH. Tidemark LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $39,000. Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $92,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $2,089,000. Armistice Capital LLC raised its stake in shares of Aurinia Pharmaceuticals by 57.7% in the 4th quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after purchasing an additional 3,488,000 shares during the period. Finally, Privium Fund Management UK Ltd acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $593,000. Institutional investors and hedge funds own 36.83% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- How to Use the MarketBeat Dividend Calculator
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- What is a Low P/E Ratio and What Does it Tell Investors?
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.